RBC Capital Markets has upgraded Neumora Therapeutics (NMRA) from sector perform to outperform, citing the company's promising pipeline beyond neurology. The firm raised its price target to $7, indicating a potential upside of approximately 213% from the November 28 closing price. Analyst Brian Abrahams emphasized the potential of NMRA-215, an NLRP3 inhibitor in preclinical development for obesity and Parkinson's disease. Despite caution on later-stage programs, any success in these areas could enhance the company's valuation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.